These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1812 related items for PubMed ID: 32860163

  • 1. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R, Kishino E, Saitoh W, Koike Y, Kurebayashi J.
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [Abstract] [Full Text] [Related]

  • 2. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ.
    Am J Health Syst Pharm; 2019 Aug 01; 76(16):1183-1202. PubMed ID: 31369120
    [Abstract] [Full Text] [Related]

  • 3. HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
    Zhou Y, Jin X, Ma J, Ding D, Huang Z, Sheng H, Yan Y, Pan Y, Wei T, Wang L, Wu H, Huang H.
    Cancer Res; 2021 Mar 15; 81(6):1486-1499. PubMed ID: 33419772
    [Abstract] [Full Text] [Related]

  • 4. Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
    Iida M, Toyosawa D, Nakamura M, Tsuboi K, Tokuda E, Niwa T, Ishida T, Hayashi SI.
    Breast Cancer; 2020 Sep 15; 27(5):963-972. PubMed ID: 32297248
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC, Lee SS, Abraham J.
    Semin Oncol; 2017 Dec 15; 44(6):385-394. PubMed ID: 29935900
    [Abstract] [Full Text] [Related]

  • 6. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Belli S, Esposito D, Ascione CM, Messina F, Napolitano F, Servetto A, De Angelis C, Bianco R, Formisano L.
    Cancer Lett; 2024 Jul 01; 593():216968. PubMed ID: 38788968
    [Abstract] [Full Text] [Related]

  • 7. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
    Kishino E, Ogata R, Saitoh W, Koike Y, Ohta Y, Kanomata N, Kurebayashi J.
    Breast Cancer; 2020 May 01; 27(3):415-425. PubMed ID: 31823286
    [Abstract] [Full Text] [Related]

  • 8. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, Sawada GA, Gelbert LM, Shannon HE, Sanchez-Martinez C, De Dios A.
    Drug Metab Dispos; 2015 Sep 01; 43(9):1360-71. PubMed ID: 26149830
    [Abstract] [Full Text] [Related]

  • 9. Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.
    Harada M, Morikawa M, Ozawa T, Kobayashi M, Tamura Y, Takahashi K, Tanabe M, Tada K, Seto Y, Miyazono K, Koinuma D.
    Cancer Sci; 2019 Jan 01; 110(1):209-220. PubMed ID: 30343527
    [Abstract] [Full Text] [Related]

  • 10. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK, Tao N, Lee KM, Huerta M, Arlt H, Mullarkey T, Troy S, Arteaga CL, Bihani T.
    Breast Cancer Res; 2019 Dec 18; 21(1):146. PubMed ID: 31852484
    [Abstract] [Full Text] [Related]

  • 11. The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time.
    Ono M, Oba T, Shibata T, Ito KI.
    J Cancer Res Clin Oncol; 2021 Nov 18; 147(11):3211-3224. PubMed ID: 34244855
    [Abstract] [Full Text] [Related]

  • 12. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Fang H, Huang D, Yang F, Guan X.
    Breast Cancer Res Treat; 2018 Apr 18; 168(2):287-297. PubMed ID: 29236235
    [Abstract] [Full Text] [Related]

  • 13. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D.
    Breast Cancer Res Treat; 2017 Nov 18; 166(1):41-54. PubMed ID: 28741274
    [Abstract] [Full Text] [Related]

  • 14. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
    Whittle JR, Vaillant F, Surgenor E, Policheni AN, Giner G, Capaldo BD, Chen HR, Liu HK, Dekkers JF, Sachs N, Clevers H, Fellowes A, Green T, Xu H, Fox SB, Herold MJ, Smyth GK, Gray DHD, Visvader JE, Lindeman GJ.
    Clin Cancer Res; 2020 Aug 01; 26(15):4120-4134. PubMed ID: 32245900
    [Abstract] [Full Text] [Related]

  • 15. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J, Ma CX.
    Curr Oncol Rep; 2020 May 16; 22(6):57. PubMed ID: 32415339
    [Abstract] [Full Text] [Related]

  • 16. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial.
    Arnedos M, Bayar MA, Cheaib B, Scott V, Bouakka I, Valent A, Adam J, Leroux-Kozal V, Marty V, Rapinat A, Mazouni C, Sarfati B, Bieche I, Balleyguier C, Gentien D, Delaloge S, Lacroix-Triki M, Michiels S, Andre F.
    Ann Oncol; 2018 Aug 01; 29(8):1755-1762. PubMed ID: 29893769
    [Abstract] [Full Text] [Related]

  • 17. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
    Corona SP, Generali D.
    Drug Des Devel Ther; 2018 Aug 01; 12():321-330. PubMed ID: 29497278
    [Abstract] [Full Text] [Related]

  • 18. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
    Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL.
    Nat Commun; 2019 Mar 26; 10(1):1373. PubMed ID: 30914635
    [Abstract] [Full Text] [Related]

  • 19. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
    Sammons SL, Topping DL, Blackwell KL.
    Curr Cancer Drug Targets; 2017 Mar 26; 17(7):637-649. PubMed ID: 28359238
    [Abstract] [Full Text] [Related]

  • 20. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.
    Sammons S, Shastry M, Dent S, Anders C, Hamilton E.
    Clin Breast Cancer; 2020 Feb 26; 20(1):1-11. PubMed ID: 31780379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 91.